Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11918609-B2
Publication Date
2024-03-05
Expiration Date
Abstract
The present invention provides a method for treating wounds by applying cells as described in this application. In one aspect the method provides treatment for cutaneous wounds. In general embodiments the cells are delivered to the wound without being attached to a functionalized substrate in the delivery vehicle.
Core Innovation
The invention relates to methods to promote cutaneous burn healing in a subject by administering cells in an effective amount and for a time sufficient to promote healing. The cells are non-embryonic non-germ cells that express CD90 and oct4 or telomerase, and are not delivered from a functionalized substrate.
The disclosed cells are not transformed, not tumorigenic, and have a normal karyotype. The method is directed to cutaneous burn healing and wound-healing uses, including promoting wound closure and tissue restoration in cutaneous wounds.
The document states that administering the specified cells promotes re-epithelialization, angiogenesis, and especially lymphangiogenesis via direct and paracrine/trophic effects, including mechanisms involving secreted factors. The disclosed results include improved wound closure and improved functional lymphatic drainage in mouse models, including secondary lymphedema and lymph node transplantation with edema reduction and lymphatic collector restoration.
Claims Coverage
The partial claim set includes one independent claim directed to promoting cutaneous burn healing using specified non-embryonic non-germ cells under constraints on delivery, cell markers, and cell safety attributes. Dependent claims further narrow administration route and formulation, and refine or add cell attribute definitions, including telomerase expression and differentiation capability across embryonic lineages.
Non-embryonic non-germ cells not from a functionalized substrate
The method administering cells to promote cutaneous burn healing, wherein the cells are not delivered from a functionalized substrate and are non-embryonic non-germ cells.
Cells expressing CD90 and oct4 or telomerase
The method wherein the cells are non-embryonic non-germ cells that express CD90 and oct4 or telomerase.
Not transformed, not tumorigenic, and normal karyotype
The method wherein the cells are not transformed, are not tumorigenic, and have a normal karyotype.
Topical administration to the burn
The cells are administered to the burn topically.
Injection delivery to the burn
The cells are administered to the burn by injection.
Liquid cell suspension formulation
The cells are administered in a liquid cell suspension.
Telomerase-expressing cells
The cells express telomerase.
Differentiation across at least two embryonic lineages
The cells can differentiate into at least one cell type from at least two of the endodermal, ectodermal, and mesodermal embryonic lineages.
Across the independent claim and its dependents, the central coverage is a wound/burn healing method using non-embryonic non-germ cells expressing CD90 and oct4 or telomerase, with explicit constraints that the cells are not delivered from a functionalized substrate and are not transformed, not tumorigenic, and have a normal karyotype. Dependent coverage further specifies administration route, a liquid cell suspension formulation, telomerase expression, and a differentiation capability spanning embryonic lineages.
Stated Advantages
Promotes cutaneous burn healing in a subject.
Promotes re-epithelialization, angiogenesis, and especially lymphangiogenesis.
Improves wound closure.
Improves functional lymphatic drainage, including edema reduction and lymphatic collector restoration in lymph node transplantation models.
Documented Applications
Cutaneous burn healing in a subject, using administration of non-embryonic non-germ cells with specified markers and safety attributes.
Wound healing of cutaneous wounds, including models supporting improved lymphangiogenesis and functional lymphatic drainage, including secondary lymphedema and lymph node transplantation with edema reduction.
Interested in licensing this patent?